Biocad continues to increase the number of clinical trials of its drugs


Biocad biotech company continues to increase the number of clinical trials of drugs for the treatment of oncological, autoimmune and orphan diseases. Since 2020, the company has doubled the number of studies conducted, the Biocad press service reported.

According to the report, Biocad is currently conducting 37 clinical trials of drugs for the treatment of socially significant diseases, including melanoma, non-small cell lung cancer, neuroblastoma, cervical cancer, axial spondyloarthritis, multiple sclerosis, and others. The company’s clinical trials take place in Russia, the Republic of Belarus, China, and Europe.

“Biocad not only continues its current clinical trials, but also plans to start testing new drugs, opening up the opportunity for patients in Russia and abroad to get early access to innovative therapies. This year, more than 2,400 people have become participants in our trials. Next year, we expect more than 3,500 healthy volunteers and patients to take part in the company’s clinical trials,” said Yulia Linkova, Vice President for Clinical Development and Research at Biocad.

Today, the company is actively recruiting participants for clinical trials of axial spondyloarthritis, melanoma, and neuroblastoma. In addition, Biocad is preparing to recruit participants for a trial of a gene therapy drug for the treatment of spinal muscular atrophy, as well as in clinical trials of a drug for the treatment of systemic scleroderma and Devic’s disease.

You can ask questions about participation in a clinical trial by calling the hotline 8 (800) 511-00-37 or at .

In addition to the research of new drugs, the company continues two international trials of Prolgolimab, an original drug registered in Russia and the Republic of Belarus for the treatment of inoperable or metastatic melanoma. The DOMAJOR trial with the indication of non-small cell lung cancer (NSCLC), and FERMATA, with the indication of cervical cancer. Clinical trials of the drug are taking place both in Russia and in China, and the DOMAJOR trial also includes participants from the European Union.

As it became known earlier, Biocad has created an information platform for clinical trials.


Exit mobile version